Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | PTGFR | P43088 | 5/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | RBP4 | P02753 | 1/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.33 |
| ▸ | NPC1 | O15118 | 4/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15187901 | 0.85 | AAK1 (0.47) | PTGDR2AAK1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL9953037 | 0.85 | PTGDR2 (0.40) | PTGDR2PTGFRARRBP4AAK1 | |
| SCHEMBL15822741 | 0.83 | AAK1 (0.33) | AAK1 | |
| SCHEMBL16428016 | 0.81 | PTGDR2 (0.38) | PTGDR2PTGFRARRBP4AAK1 | |
| SCHEMBL12614400 | 0.79 | PTGDR2 (0.40) | PTGDR2PTGFRARRBP4AAK1 | |
| SCHEMBL15902958 | 0.77 | BACE1 (0.31) | — | |
| SCHEMBL15902955 | 0.77 | BACE1 (0.31) | — | |
| SCHEMBL15902960 | 0.77 | BACE1 (0.31) | — | |
| SCHEMBL28466237 | 0.77 | BACE1 (0.31) | — | |
| SCHEMBL16462659 | 0.76 | PTGDR2 (0.33) | PTGDR2PTGFRARRBP4AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3353163-B1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-05 | — | — | EP | disclosed |
| US-20180334447-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2018-11-22 | — | — | US | disclosed |
| EP-3353163-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | Janssen Pharmaceutica, N.V. (BE) | 2018-08-01 | — | — | EP | disclosed |
| WO-2017050978-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334447-A1 | 2,3,4,5-TETRAHYDROPYRIDIN-6-AMINE DERIVATIVES | BACE1, BACE2, APP | PTGDR2 1444/4885PTGFR 1733/4885AR 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.